Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 4/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | TGM2 | P21980 | 5/20 | 0.43 |
| ▸ | F13A1 | P00488 | 4/20 | 0.43 |
| ▸ | TGM1 | P22735 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634287 | 0.87 | IGF1R (0.47) | MERTKAXLTYRO3IGF1R | |
| SCHEMBL1632322 | 0.85 | HRH3 (0.47) | MERTKAXLTYRO3IGF1R | |
| SCHEMBL1633516 | 0.84 | IGF1R (0.49) | MERTKAXLTYRO3IGF1RSYK | |
| SCHEMBL1634295 | 0.83 | IGF1R (0.44) | MERTKAXLTYRO3IGF1R | |
| SCHEMBL1632419 | 0.82 | IGF1R (0.44) | MERTKAXLTYRO3IGF1R | |
| SCHEMBL1633172 | 0.80 | KDM4E (0.59) | MERTKAXLTYRO3IGF1R | |
| SCHEMBL1634388 | 0.79 | GRIN2D (0.46) | GPR119IGF1RMAPTSYK | |
| SCHEMBL1632893 | 0.77 | MERTK (0.49) | MERTKAXLTYRO3IGF1RMAPT | |
| SCHEMBL1633896 | 0.76 | TBK1 (0.48) | GPR119JAK2IGF1RSYK | |
| SCHEMBL12725725 | 0.76 | GPR119 (0.60) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MERTK 3809/4885GPR119 602/4885TGM2 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.